| HOME >> MEDICINE >> TECHNOLOGY |
without limiting any of the foregoing, no Regulatory Authority becomes entitled to suspend, terminate or withhold any grant, development assistance or other financial assistance to which any member of the ChemGenex Group is or may be otherwise entitled or to require or accelerate repayment of any grant, development assistance or other financial assistance previously provided to any member of the ChemGenex Group.(d)
HSRNo objection being received and the period of 30 days expiring (or earlier terminated) from the date of the filing by Cephalon CXS of a merger / acquisition notification as required under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.(e)
No prescribed occurrences(i)
Between the time beginning when the Bidder's Statement is given to ChemGenex and ending at the end of the Offer Period, none of the following occurrences happens:(A)
ChemGenex converts all or any of the ChemGenex Shares into a larger or smaller number of ChemGenex Shares;(B)
any member of the ChemGenex Group resolves to reduce its share capital in any way;(C)
any member of the ChemGenex Group enters into a buy-back agreement or resolves to approve the terms of a buy-back agreement under section 257C(1) or 257D(1) of the Corporations Act; (D)
any member of the ChemGenex Group issues shares (other than pursuant to Disclosed Options or the convertible notes on issue to Cephalon International) or grants an option over its shares, or agrees to make such an issue or grant such an option; (E)
any member of the ChemGenex Group issues, or agrees to issue, convertible notes;(F)
any member of the ChemGenex Group disposes, or agrees to dispose, of the whole, or a substantial part, of its business or property;(G)
any member of the ChemGenex Group charges, or agrees to charge, the whole, or a substantial part, of its business or property;(H)
any member of the C
'/>"/>
| SOURCE Cephalon, Inc.; ChemGenex Pharmaceuticals Limited Copyright©2010 PR Newswire. All rights reserved |